The pharmaceutical landscape in 2026 is witnessing a renewed focus on affordable, high-efficacy "anchor" therapies. A comprehensive Methotrexate Market analysis confirms that the industry has reached a valuation of approximately $680.1 million this year. While high-cost biologics continue to dominate the headlines, methotrexate remains the clinical foundation for over 60% of all autoimmune...